Historical Valuation
Arcus Biosciences Inc (RCUS) is now in the Fair zone, suggesting that its current forward PS ratio of 26.43 is considered Fairly compared with the five-year average of -6.27. The fair price of Arcus Biosciences Inc (RCUS) is between 13.51 to 21.73 according to relative valuation methord.
Relative Value
Fair Zone
13.51-21.73
Current Price：21.01
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Arcus Biosciences Inc (RCUS) has a current Price-to-Book (P/B) ratio of 5.72. Compared to its 3-year average P/B ratio of 2.51 , the current P/B ratio is approximately 128.26% higher. Relative to its 5-year average P/B ratio of 2.83, the current P/B ratio is about 102.10% higher. Arcus Biosciences Inc (RCUS) has a Forward Free Cash Flow (FCF) yield of approximately -16.10%. Compared to its 3-year average FCF yield of -17.48%, the current FCF yield is approximately -7.91% lower. Relative to its 5-year average FCF yield of -7.31% , the current FCF yield is about 120.18% lower.
P/B
Median3y
2.51
Median5y
2.83
FCF Yield
Median3y
-17.48
Median5y
-7.31
Competitors Valuation Multiple
AI Analysis for RCUS
The average P/S ratio for RCUS competitors is 47.68, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS.N) exhibits a P/S ratio of 26.43, which is -44.56% above the industry average. Given its robust revenue growth of -45.83%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for RCUS
1Y
3Y
5Y
Market capitalization of RCUS increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of RCUS in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is RCUS currently overvalued or undervalued?
Arcus Biosciences Inc (RCUS) is now in the Fair zone, suggesting that its current forward PS ratio of 26.43 is considered Fairly compared with the five-year average of -6.27. The fair price of Arcus Biosciences Inc (RCUS) is between 13.51 to 21.73 according to relative valuation methord.
What is Arcus Biosciences Inc (RCUS) fair value?
RCUS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Arcus Biosciences Inc (RCUS) is between 13.51 to 21.73 according to relative valuation methord.
How does RCUS's valuation metrics compare to the industry average?
The average P/S ratio for RCUS's competitors is 47.68, providing a benchmark for relative valuation. Arcus Biosciences Inc Corp (RCUS) exhibits a P/S ratio of 26.43, which is -44.56% above the industry average. Given its robust revenue growth of -45.83%, this premium appears unsustainable.
What is the current P/B ratio for Arcus Biosciences Inc (RCUS) as of Jan 10 2026?
As of Jan 10 2026, Arcus Biosciences Inc (RCUS) has a P/B ratio of 5.72. This indicates that the market values RCUS at 5.72 times its book value.
What is the current FCF Yield for Arcus Biosciences Inc (RCUS) as of Jan 10 2026?
As of Jan 10 2026, Arcus Biosciences Inc (RCUS) has a FCF Yield of -16.10%. This means that for every dollar of Arcus Biosciences Inc’s market capitalization, the company generates -16.10 cents in free cash flow.
What is the current Forward P/E ratio for Arcus Biosciences Inc (RCUS) as of Jan 10 2026?
As of Jan 10 2026, Arcus Biosciences Inc (RCUS) has a Forward P/E ratio of -5.73. This means the market is willing to pay $-5.73 for every dollar of Arcus Biosciences Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Arcus Biosciences Inc (RCUS) as of Jan 10 2026?
As of Jan 10 2026, Arcus Biosciences Inc (RCUS) has a Forward P/S ratio of 26.43. This means the market is valuing RCUS at $26.43 for every dollar of expected revenue over the next 12 months.